Synthetic Lethality Conference, Boston, 2017
Organiser Name: Hanson Wade
Contact: Charlotte Harrison
info@hansonwade.com
+1 212 537 5898
Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more will be sharing their insight and lessons learned, collectively enabling the community to:
- Achieve Efficacy across Contexts: Define the key steps required to identify and therapeutically exploit robust synthetic lethal interactions that are conserved across a variety of defined contexts
- Optimize Patient Stratification: Streamline clinical trials by improving the recruitment and stratification of patients, increasing efficiency
- Apply Lessons Learned from PARP Inhibitors: Analyze key aspects of the development of PARP inhibitors through case studies, and determine how we can use these insights to advance R and D of new synthetic lethal drugs
- Exploit Key Targets of Mechanisms of Resistance: Assess the most effective methods for identifying and utilizing mechanisms of resistance to optimize cancer treatment
- Harness Bioinformatics and Computational Approaches: Exploring the latest advances in identifying clinically relevant synthetic lethal interactions from genome widescreens
Join your peers in Boston to gain unique and novel insights into methods for accelerating your synthetic lethal drug development.
